BridgeMD
A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725
EU CTIS ID: 2025-521973-16-00
What this study is testing
Effectiveness: To evaluate the therapeutic potential of BCX17725 in adult and adolescent participants with NS. Safety: To evaluate the safety and tolerability of BCX17725 when administered for 12 weeks in adult and adolescent participants with NS. PK:To characterize BCX17725 concentrations in serum of adult and adolescent participants with NS.
- Phase I and Phase II (Integrated)- Other
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Able to provide written informed consent. Adolescent participants should provide assent (age determined by applicable institutional policy) with parent/legal guardian consent.
- Male or non-pregnant, non-lactating female, aged 12 to 65 years, inclusive, with a confirmed diagnosis of NS. Note: Participants without pre-existing documentation of SPINK5 gene variant(s) confirming NS diagnosis will be required to provide a blood sample for genetic testing at screening.
- IGA score ≥ 3 and an IASI score of ≥ 16 at screening and Day 1 (baseline).
- Females of childbearing potential and males with female partners of childbearing potential, must agree to follow the contraception requirements outlined in Section 5.3 of the protocol from screening until 90 days after the last dose of BCX17725.
- Participant (or, where applicable, parent/legal guardian) is willing and able to understand and comply with all applicable study requirements, including:a.a. Available to complete the entire study duration; b: Able to understand the study procedures including the ability to complete any self assessment questionnaires or instruments; c: Willing to have skin strip samples collected
You likely can't join if
- Apart from a diagnosis of NS, any clinically significant disease or condition (eg, medical, psychiatric, or social) that, in the opinion of the investigator, would interfere with the participant’s ability to participate in the study or increase the risk of participation for that participant.
- Any abnormal laboratory parameter at screening or Day 1 that, in the opinion of the investigator, is clinically significant and relevant for this study, including but not limited to those listed below. Enrollment of a participant with a laboratory value outside of the reference range may be permissible if the abnormality is documented by the investigator not to be of clinical significance. a. AST, ALT, or total bilirubin value > 1.5 × ULN b. Platelet count < 150,000/µL
- History of anaphylaxis or other severe reaction to any biologic or protein therapeutic agent, which, in the opinion of the investigator or sponsor medical monitor, should contraindicate their participation in this study.
- History of sensitivity to any component of the IMP.
- Receipt of any investigational drug, systemic biologic, or systemic immunoglobulin within 8 weeks prior to Day 1 or anticipated receipt during the study (excluding potential receipt of BCX17725 during the study). Note: Individuals who participate in Part 3 may additionally participate in Part 4, providing they meet all applicable eligibility criteria for Part 4 and experienced no significant safety concerns related to BCX17725 administration in Part 3. Part 3 participants qualifying for Part 4 enrollment will be subject to the washout period as described above
- Use of systemic retinoids, other systemic immunosuppressants, systemic corticosteroids, or phototherapy within 4 weeks prior to Day 1 or anticipated use during the study.
See the full eligibility criteria
Who can join
- Able to provide written informed consent. Adolescent participants should provide assent (age determined by applicable institutional policy) with parent/legal guardian consent.
- Male or non-pregnant, non-lactating female, aged 12 to 65 years, inclusive, with a confirmed diagnosis of NS. Note: Participants without pre-existing documentation of SPINK5 gene variant(s) confirming NS diagnosis will be required to provide a blood sample for genetic testing at screening.
- IGA score ≥ 3 and an IASI score of ≥ 16 at screening and Day 1 (baseline).
- Females of childbearing potential and males with female partners of childbearing potential, must agree to follow the contraception requirements outlined in Section 5.3 of the protocol from screening until 90 days after the last dose of BCX17725.
- Participant (or, where applicable, parent/legal guardian) is willing and able to understand and comply with all applicable study requirements, including:a.a. Available to complete the entire study duration; b: Able to understand the study procedures including the ability to complete any self assessment questionnaires or instruments; c: Willing to have skin strip samples collected
What rules you out
- Apart from a diagnosis of NS, any clinically significant disease or condition (eg, medical, psychiatric, or social) that, in the opinion of the investigator, would interfere with the participant’s ability to participate in the study or increase the risk of participation for that participant.
- Any abnormal laboratory parameter at screening or Day 1 that, in the opinion of the investigator, is clinically significant and relevant for this study, including but not limited to those listed below. Enrollment of a participant with a laboratory value outside of the reference range may be permissible if the abnormality is documented by the investigator not to be of clinical significance. a. AST, ALT, or total bilirubin value > 1.5 × ULN b. Platelet count < 150,000/µL
- History of anaphylaxis or other severe reaction to any biologic or protein therapeutic agent, which, in the opinion of the investigator or sponsor medical monitor, should contraindicate their participation in this study.
- History of sensitivity to any component of the IMP.
- Receipt of any investigational drug, systemic biologic, or systemic immunoglobulin within 8 weeks prior to Day 1 or anticipated receipt during the study (excluding potential receipt of BCX17725 during the study). Note: Individuals who participate in Part 3 may additionally participate in Part 4, providing they meet all applicable eligibility criteria for Part 4 and experienced no significant safety concerns related to BCX17725 administration in Part 3. Part 3 participants qualifying for Part 4 enrollment will be subject to the washout period as described above
- Use of systemic retinoids, other systemic immunosuppressants, systemic corticosteroids, or phototherapy within 4 weeks prior to Day 1 or anticipated use during the study.
- Use of ultra-high to medium potency topical corticosteroids (WHO Classes 1 to 5 or equivalent; see Appendix 3) within 2 weeks prior to Day 1 or anticipated use during the study.
- Participant is pregnant, planning to become pregnant, or having been pregnant within 90 days before Day 1, or lactating.
- Any other skin disease that may interfere with planned NS skin evaluations.
- Any infection requiring treatment with systemic antibiotics, antivirals, antiparasitics, or antifungals within 2 weeks prior to Day 1.
- History of malignancy within 5 years prior to screening, with exception of adequately treated non-melanoma skin or superficial bladder cancer, curatively treated carcinoma in situ of the cervix, or other curatively treated solid tumor deemed by the investigator and medical monitor to be at low risk for recurrence.
- Any clinically significant history of a cardiovascular abnormality, including but not limited to angina, known coronary artery disease, myocardial infarction, clinically significant cardiac arrhythmias, left ventricular hypertrophy, cardiomyopathy, or aortic stenosis.
- History of significant drug or alcohol abuse in the 6 months prior to screening or a positive drugs of abuse screen (not supported by a legitimate prescription) at screening.
- Positive test result for HIV at screening.
- Active hepatitis B virus infection, determined by positive test result for hepatitis B surface antigen, at screening.
- Active hepatitis C infection, determined as HCV RNA above the limit of detection in participants with positive HCV antibody titer, at screening.
The study team makes the final eligibility decision.
Where it's taking place
- Australia
- United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Australia; United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.